<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - Pfizer’s COVID-19 Candidate Has Moderate Side Effects
Image Overlay - Pfizer’s COVID-19 Candidate Has Moderate Side Effects

Pfizer’s COVID-19 Candidate Has Moderate Side Effects

Pfizer’s COVID-19 Candidate Has Moderate Side Effects

Pfizer has announced that participants in their phase III clinical trial had moderate side effects. More than 12,000 people have received a second round of the vaccine, with 29,000 enrolled in the trial. For phase III, Pfizer would like to increase enrollment to 44,000 including people as young as 16 and those with HIV and hepatitis C or B. Yourway’s primary and secondary packaging capabilities integrate seamlessly with our storage & distribution and premium courier services to enhance supply chain efficiency and facilitate shorter lead times compared to other clinical services and logistics companies.

Back to Index
Media

Upcoming Events

Clinical Outsourcing Group (COG)

October 21-22, 2025
Burlingame, California

Precision in Pharma Supply Chain & Logistics Summit

November 17-18, 2025
Revere Hotel Boston Common

Media

Articles

Case study: Coordinating a complex intercontinental shipment on a short timeline

Open chat
Come chat with us!
Hello! How can I help you?